By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pluristem Therapeutics 

New York  New York    U.S.A.
Phone: n/a Fax: n/a



Company News
Pluristem Therapeutics (PSTI) Provides Shareholder Update On Corporate And Clinical Developments 5/22/2017 8:17:07 AM
Pluristem Therapeutics (PSTI) Announces Promising Results From Non-Human Primate Pilot Study Of PLX-R18 In Acute Radiation Syndrome 5/3/2017 10:31:42 AM
Pluristem Therapeutics (PSTI) Reaches Milestone Of 100 Granted Patents, Including Coverage Of Leading Indications In Major Markets 4/19/2017 8:41:23 AM
Pluristem Therapeutics (PSTI) Launches Co-CEO Structure And Appoints New CFO 3/30/2017 8:37:18 AM
Pluristem Therapeutics (PSTI) Release: Company Receives Clearance From Germany To Initiate Its Multinational Phase III Trial In Critical Limb Ischemia Targeting Early Conditional Marketing Approval 1/17/2017 12:41:36 PM
Pluristem Therapeutics (PSTI) Release: Company’s Phase III Study Of PLX-PAD Cells For The Treatment Of Critical Limb Ischemia Cleared By U.S. FDA 1/10/2017 11:04:14 AM
Pluristem Therapeutics (PSTI) Release: Jumps as the FDA Clears Critical Limb Ischemia Trial 1/10/2017 6:40:48 AM
Pluristem Therapeutics (PSTI) And New York Blood Center To Collaborate In Evaluating PLX-R18 As An Adjuvant Therapy To Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD 12/28/2016 9:05:57 AM
Newly Formed Company Established by Pluristem Therapeutics (PSTI) and Sosei CVC 12/20/2016 7:15:11 AM
Pluristem Therapeutics (PSTI)’s PLX-R18 Advances Into Second Cohort Of Dose Selection Study For Treatment Of Acute Radiation Syndrome 12/6/2016 9:12:18 AM